Upper gastrointestinal bleeding in patients treated by low-dose aspirin;Hémorragies digestives hautes et aspirine à faible dose

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 3, 2001, Pages 233-238

  Capet, Corinne ^a   Czernichow, Pierre ^a   Dupas, Jean Louis ^b   Goria, Odile ^a,b   Gouérou, Hervé ^a   Hochain, Patrick ^b   Amouretti, Michel ^c   Herman, Hélène ^a   Colin, Raymond ^d  

^a Faculté de Médecine Pharmacie   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Laboratoire Searle

Author keywords

Case control study; Gastrointestinal bleeding; Low dose aspirin; Peptic ulcer

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FRANCE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; DUODENAL ULCER; FEMALE; FRANCE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STOMACH ULCER;

EID: 0035020386     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Gastric adaptation occurs with aspirin administration in man
2. Effect of aspirin on the human stomach in normals: Endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration
3. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy
4. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side-effects
5. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomised trial in patients with mechanical prosthetic heart valves
6. Antiplatelet therapy
7. Collaborative overview of randomised trials of antiplatelet therapy II - Maintenance of vascular graft or arterial patency by antiplatelet therapy
8. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
9. Final report on the aspirin component of the ongoing physicians' health study
10. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin. Analysis of gastrointestinal bleeding during the UK-TIA trial
11. Aspirin and the stomach
12. Low-dose aspirin: An unrecognised cause of gastric mucosal damage
13. Aspirin use in patients with major gastrointestinal bleeding and peptic-ulcer
14. Salicylate-induced gastrointestinal bleeding: Comparison between soluble buffered, enteric-coated, and intravenous administration
15. Prophylactic aspirin and risk of peptic ulcer bleeding
16. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
17. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
18. Upper gastrointestinal bleeding in relation to previous use of analgesics and non steroidal anti-inflammatory drugs
19. Gastric adaptation: Studies in humans during continuous aspirin administration
20. Human gastric mucosal bleeding induced by low-dose aspirin, but not warfarin
21. Gastric mucosal bleeding: What dose of aspirin is safe?
22. Prognostic factors in upper gastrointestinal bleeding
23. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: A population-based study
24. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United-Kingdom
25. Significant role of aspirin use in patients with oesophagitis
26. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
27. CAST: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke
28. Extra-cranial bleeding and other symptoms due to low-dose aspirin and low-intensity oral anticoagulation
29. Gastrointestinal blood loss with low-dose (325 mg) plain and enteric-coated aspirin administration
30. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
31. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events
32. Objective evidence of aspirin use in both ulcer nonulcer upper and lower gastrointestinal bleeding
33. Aspirin and bleeding peptic ulcer in the elderly
34. The current spectrum of peptic ulcer disease in the older age groups
35. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa
36. Asymptomatic chronic blood loss in patients taking aspirin or warfarin for cardiovascular disease
37. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
38. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
39. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs
40. Gastric protection by misoprostol against 1 300 mg of aspirin. An endoscopic study
41. Epidémiologie et traitement des lésions gastroduodénales provoquées par les médicaments anti-inflammatoires non stéroïdiens